Tumor-induced hypercalcemia in a patient with extensive soft tissue sarcoma: effects of bisphosphonate therapy and surgery.
Tumor-induced hypercalcemia (TIH) is a frequent complication of advanced cancer, but it has been rarely reported in patients with sarcoma. We describe the case of a young female patient with TIH and with an extensive synoviosarcoma of the left lower limb destroying the bony structures. Hypercalcemia was severe (18.3 mg/dl) and accompanied by low serum Pi and suppressed parathyroid hormone (PTH) and 1,25(OH)2 vit D3 serum concentrations. Hypercalcemia was successfully treated with ibandronate, a new third-generation bisphosphonate, and radical surgery was performed when the patient was normocalcemic. Circulating levels of PTH-related protein (PTHrP) were elevated at 22.5 pmol/L (NI < 9). PTHrP levels did not change after successful therapy of TIH, in contrast with PTH, which increased sharply. PTHrP levels were normalized after radical surgery. Moreover, low serum Pi with reduced threshold for phosphate excretion and increased tubular calcium reabsorption supported the notion that PTHrP was indeed the essential mediator of paraneoplastic hypercalcemia in this case despite the extensive bone destruction.
Oleffe
V
V
Bone Metabolism Unit, Clinique H.J. Tagnon, Institut Jules Bordet, Université Libre de Bruxelles, Belgium.
Dumon
J C
JC
Body
J J
JJ
D000328:Adult; D001862:Bone Resorption / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology / Q000601:surgery; D000077557:Ibandronic Acid; D007866:Leg; D013584:Sarcoma, Synovial / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D013997:Time Factors
D004164:Diphosphonates; D000077557:Ibandronic Acid